The problem with relying on profit-driven models to produce pandemic drugs
{{output}}
In this article, we explain why profit-driven models for developing treatments for epidemic pathogens produce sub-optimal and sometimes negative public health outcomes. Using the example of the drug remdesivir, we demonstrate how the divergence of private ince... ...
